Hepatobiliary complications of hematopoietic cell transplantation, 40 years on

Hepatology

Volumn 51, Issue 4, 2010, Pages 1450-1460

  McDonald, George B ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ALPHA TOCOPHEROL; ANTITHROMBIN III; ANTIVIRUS AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEFIBROTIDE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLUTAMINE; HEPARIN; IMATINIB; IRON CHELATING AGENT; ITRACONAZOLE; MELPHALAN; NITRATE; PHENYTOIN; PLACEBO; PREDNISONE; PROSTAGLANDIN E1; RAPAMYCIN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; BACTERIAL INFECTION; BILE DUCT STONE; BILIARY TRACT DISEASE; CHOLANGITIS LENTA; CHOLELITHIASIS; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; COMA; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG MEGADOSE; GALLBLADDER DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HEPATOMEGALY; HEREDITY; HUMAN; HYPERAMMONEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; IRON CHELATION; IRON OVERLOAD; LIVER ABSCESS; LIVER CANCER; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER INJURY; LIVER NECROSIS; LYMPHOPROLIFERATIVE DISEASE; MULTIACINAR COLLAPSE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SINUSOIDAL OBSTRUCTION SYNDROME; STELLATE CELL; TREATMENT FAILURE; VIRUS HEPATITIS; WHOLE BODY RADIATION;

BILIARY TRACT DISEASES; CHOLESTASIS; GALLSTONES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HEPATITIS, VIRAL, HUMAN; HUMANS; IRON OVERLOAD; LIVER DISEASES; MYCOSES;

EID: 77950598635     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23533     Document Type: Review

References (50)

1. Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In: Wingard JR, Bowden RA, eds. Management of Infection in Oncology Patients. London, UK: Martin Dunitz; 2003:321-342.
2. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-1983.
3. Marotta G, Tozzi M, Sammassimo S, Defina M, Raspadori D, Gozzetti A, et al. Complete resolution of hepatic aspergillosis after nonmyeloa-blative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology 2005;10:383-386.
4. Deschenes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. HEPA-TOLOGY 2004;39:867-868.
5. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-624.
6. Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol 2007;102:449-451.
7. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection after bone marrow transplantation: A cohort study with 10 year follow-up. HEPATOLOGY 1999;29: 1893-1899.
8. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch G, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:76-82.
9. Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation 2006;82:141-142.
10. Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood 2002;99:4245-4246.
11. Jacobsohn DA, Emerick KM, Scholl P, Melin-Aldana H, O'Gorman M, Duerst R, et al. Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangi-opathy. Pediatrics 2004;113:e122-e127.
12. McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut 2008;57:987-1003.
13. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leukemia Res 2007;31: 599-604.
14. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008;112: 2973-2978.
15. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:506-510.
16. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. HEPATOLOGY 2005;41:345-352.
17. Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis 2002;22:27-41.
18. Coppell JA, Richardson PG, Soiffer RJ, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course and outcome. Biol Blood Marrow Transplant 2010;16:157-168.
19. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venocclusive disease of the liver after marrow transplantation: Histo-logic correlates of clinical signs and symptoms. HEPATOLOGY 1994;19: 1171-1180.
20. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kal-horn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101:2043-2048.
21. McCune JS, Batchelder AL, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: A phase II trial in patients with hematologic malignancy. Clinical Pharmacology and Therapeutics 2009;85:615-622.
22. McCune JS, Batchelder A, Deeg HJ, Gooley TA, Cole SL, Phillips B, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxic-ity, and mortality. Biol Blood Marrow Transplant 2007;13:853-862.
23. Sakai M, Strasser SI, Shulman HM, McDonald SJ, Schoch HG, McDonald GB. Severe hepatocellular necrosis after hematopoietic cell transplant: Incidence, etiology, and outcome. Bone Marrow Transplant 2009;44:441-447.
24. Coy DL, Ormazabal A, Godwin JD, Lalani T. Imaging evaluation of pulmonary and abdominal complications following hematopoietic stem cell transplantation. Radiographics 2005;25:305-317.
25. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant 1993;11:21-26.
26. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995;59:1015-1022.
27. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005;67:272-277.
28. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-1736.
29. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busul-fan toxicity in cultured murine hepatocytes. Pharmacology 2000;60: 143-154.
30. Jenke A, Freiberg-Richter J, Wilhelm S, Freund M, Renner UD, Born-hauser M, et al. Accidental busulfan overdose during conditioning for stem cell transplantation. Bone Marrow Transplantation 2005;35:125-128.
31. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharma-cokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857-864.
32. Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47: 1488-1494.
33. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chauhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily IV busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008;14:220-228.
34. Corbacioglu S. The prospective study on the incidence and outcome of VOD with the prophylactic use of defibrotide in paediatric stem cell transplantation has completed enrollment: update on the VOD-DF study. Bone Marrow Transplant 2009;43:S34-S35.
35. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multicen-ter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; in press.
36. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation. HEPATOLOGY 1988;8:463-470.
37. Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prum-baum M, et al. Chronic graft-vs-host disease of the liver: presentation as an acute hepatitis. HEPATOLOGY 2000;32:1265-1271.
38. Leisenring W, Martin P, Petersdorf E, Regan A, Aboulhosn N, Stern J, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006;108:749-755.
39. Yagi T, Karasuno T, Hasegawa T, Yasumi M, Kawamoto S, Murakami M, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplantation 2000;25:1003-1005.
40. Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007;13:74-81.
41. Alnusair MM, DeMagalhaes-Silverman M, Silverman WB. The role of ERCP in patients with pancreatico-biliary problems in the setting of hematopoietic stem cell transplant. Gastrointest Endosc 2006;63: 655-659.
42. Frere P, Canivet JL, Gennigens C, Rebeix JP, Fillet G, Beguin Y. Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplantation 2000;26:343-345.
43. Appelbaum FR, Forman SJ, Negrin RS, Blume KG. Thomas' Hemato-poietic Cell Transplantation. 4th ed. Oxford, UK: Wiley-Blackwell Publishing; 2009.
44. Vogelsang GB, Pavletic SZ. Chronic Graft Versus Host Disease: Interdisciplinary Management. First ed. New York, NY: Cambridge University Press; 2009.
45. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992;116: 624-629.
46. Shimizu T, Kasahara M, Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. New Engl J Med 2006; 354:1536-1537.
47. Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-1624. (Pubitemid 38268950)
48. Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999;93:3259-3266.
49. Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, et al. Phlebotomy to reduce iron overload in patients cured of thalasse-mia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997;90:994-998.
50. Sudour H ML, Baumann C, Clement L, Salmon A, Bordigoni P. Focal hepatic hyperplasia following hematopoietic stem cell transplantation. Bone Marrow Transplantation 2009;43:127-132.